# Aris Constantinides

> Aris Constantinides is a debt financing investor at Kreos Capital backing Health Diagnostics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Kreos Capital](https://shizune.co/investors/profile/kreos-capital)
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Nov 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/arisconstantinides/

Aris Constantinides is a debt financing investor at Kreos Capital in London focused on Health Diagnostics and Genetics. Aris is the founder and Investment Director of NBGI Ventures, responsible for its overall strategy and management, and leads its presence in the medical technology sector. Aris established NBGI Ventures in 2001, following five years in venture capital with Deutsche Bank’s venture capital team and CSFB’s Cabot Square Capital fund. He started hiscareer at Bankers Trust as a derivatives specialist.Aris holds a B.Eng from Imperial College and a SM from MIT in Mechanical Engineering and an MBA from INSEAD.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Diagnostics | 2 | 100% |
| Genetics | 1 | 50% |
| Analytics | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |

10 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ibex Medical Analytics | Ibex Medical Analytics was conceived when its two founders were looking for ways to apply their skills to contribute to human well-being. They were captivated with the opportunity presented by applying artificial intelligence (AI) to medicine and, in particular, the potential it holds for advancing cancer care. They decided to combine theiraccumulated knowledge of AI, data science, image analysis, and machine learning, and apply it to cancer diagnostics in digital pathology.Today, Ibex is a multidisciplinary team comprised of entrepreneurs, data scientists, software engineers and medical experts, working together to realize our vision: Applying AI to cancer diagnostics, striving to improve patient outcomes and quality of life. | $10M | Debt Financing | Nov 09, 2022 |  |
| Variantyx | Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing. | $20M | Debt Financing | Oct 18, 2022 |  |

2 of 2 investments shown.

## Co-investors
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [Dell Technologies Capital](https://shizune.co/investors/profile/dell-technologies-capital) — VC Fund, 1 deal together
- [83North](https://shizune.co/investors/profile/greylock-partners-israel) — VC Fund, 1 deal together
- [Octopus Ventures](https://shizune.co/investors/profile/octopus-ventures) — VC Fund, 1 deal together
- [Planven Entrepreneur Ventures](https://shizune.co/investors/profile/planven-investments) — VC Fund, 1 deal together

## About Kreos Capital

VC Fund · London, United Kingdom

Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.

5 contacts available at Kreos Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Aris Constantinides | General Partner | https://shizune.co/investors/profile/aris-constantinides |
| Jonne de Leeuw | Venture Partner | https://shizune.co/investors/profile/jonne-de-leeuw |
| Marten Vading | General Partner | https://shizune.co/investors/profile/mrten-vading |
| Maurizio PetitBon | General Partner | https://shizune.co/investors/profile/maurizio-petitbon |
| Melissa Donohoe | Associate | https://shizune.co/investors/profile/melissa-donohoe |

## Similar investors

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

## FAQ

### What does Aris Constantinides invest in?

Aris Constantinides invests primarily in Health Diagnostics, Genetics and Analytics startups, most often at Debt Financing stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Aris Constantinides last invest?

The most recent investment recorded for Aris Constantinides closed in Nov 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co